پديدآورندگان :
Abbasi Gamasaee Niusha Department of Molecular and Cellular Science, Faculty of Advanced Sciences Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS) , Shahriari Fatemeh Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. , Javidi Mohammad Amin maj136@gmail.com Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.Department of Molecular and Cellular Science, Faculty of Advanced Sciences Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS)و
كليدواژه :
Key words: Hypericin , Breast cancer , Triple negative , low , claudin
چكيده فارسي :
Breast cancer is the most common cancer among females worldwide. In recent molecular
profiling of breast cancer which is based on hormone receptors and HER2 status along with
proliferation markers, the Triple negative subtype poses the hardest one to treat and the one
with the poorest prognosis. In this study we assessed the effect of Hepericin, a naturally
occurring chromophore, on the MDA-MB-231 cell line. This cell line represents as a Triple
negative/ low-claudin subtype. Hypericin is a fluorescent second metabolite with a broad
pharmacological spectrum. Its selective accumulation in tumor microenvironment along with
its potent photosensitizing feature made it a favorable candidate in anticancer photodynamic
therapy (PDT) and photodynamic diagnosis (PDD) studies. Yet its own proapoptotic effects on
cancerous cells has been less studied. In this study we investigated the different doses and
exposure times of Hypericin on malignant and normal cells and studied its downstream
apoptotic effects. Our results suggest that Hypericin can be a good candidate in the treatment
of Triple negative breast cancer with the least side effects on normal tissues.
